Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Interaction of myricetin, ampelopsin (dihydromyricetin), and their sulfate metabolites with serum albumin, cytochrome P450 (CYP2C9, 2C19, and 3A4) enzymes, and organic anion-transporting polypeptides (OATP1B1 and OATP2B1)

Á. Dombi, H. Kaci, K. Valentová, É. Bakos, C. Özvegy-Laczka, M. Poór

. 2024 ; 12 (5) : e70021. [pub] -

Language English Country United States

Document type Journal Article

Grant support
ÚNKP-23-4 Nemzeti Kutatási, Fejlesztési és Innovaciós Alap
23-04654S Grantová Agentura České Republiky
FK138184 Nemzeti Kutatási Fejlesztési és Innovációs Hivatal
K138518 Nemzeti Kutatási Fejlesztési és Innovációs Hivatal
BO/00381/21 Magyar Tudományos Akadémia

Myricetin (MYR) and ampelopsin (AMP, or dihydromyricetin) are flavonoid aglycones found in certain plants and dietary supplements. During the presystemic biotransformation of flavonoids, mainly sulfate and glucuronide derivatives are produced, which are the dominant metabolites in the circulation. In this study, we tested the interactions of MYR, myricetin-3'-O-sulfate (M3'S), AMP, and ampelopsin-4'-O-sulfate (A4'S) with human serum albumin (HSA), cytochrome P450 enzymes (CYPs), and organic anion-transporting polypeptides (OATPs) using in vitro models, including the recently developed method for measuring flavonoid levels in living cells. M3'S and MYR bound to albumin with high affinity, and they showed moderate displacing effects versus the Site I marker warfarin. MYR, M3'S, AMP, and A4'S exerted no or only minor inhibitory effects on CYP2C9, CYP2C19, and CYP3A4 enzymes. M3'S and MYR caused considerable inhibitory actions on OATP1B1 at low micromolar concentrations (IC50 = 1.7 and 6.4 μM, respectively), while even their nanomolar levels resulted in strong inhibitory effects on OATP2B1 (IC50 = 0.3 and 0.4 μM, respectively). In addition, M3'S proved to be a substrate of OATP1B1 and OATP2B1. These results suggest that MYR-containing dietary supplements may affect the OATP-mediated transport of certain drugs, and OATPs are involved in the tissue uptake of M3'S.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24018726
003      
CZ-PrNML
005      
20241024111245.0
007      
ta
008      
241015s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/prp2.70021 $2 doi
035    __
$a (PubMed)39344282
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Dombi, Ágnes $u Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Pécs, Hungary
245    10
$a Interaction of myricetin, ampelopsin (dihydromyricetin), and their sulfate metabolites with serum albumin, cytochrome P450 (CYP2C9, 2C19, and 3A4) enzymes, and organic anion-transporting polypeptides (OATP1B1 and OATP2B1) / $c Á. Dombi, H. Kaci, K. Valentová, É. Bakos, C. Özvegy-Laczka, M. Poór
520    9_
$a Myricetin (MYR) and ampelopsin (AMP, or dihydromyricetin) are flavonoid aglycones found in certain plants and dietary supplements. During the presystemic biotransformation of flavonoids, mainly sulfate and glucuronide derivatives are produced, which are the dominant metabolites in the circulation. In this study, we tested the interactions of MYR, myricetin-3'-O-sulfate (M3'S), AMP, and ampelopsin-4'-O-sulfate (A4'S) with human serum albumin (HSA), cytochrome P450 enzymes (CYPs), and organic anion-transporting polypeptides (OATPs) using in vitro models, including the recently developed method for measuring flavonoid levels in living cells. M3'S and MYR bound to albumin with high affinity, and they showed moderate displacing effects versus the Site I marker warfarin. MYR, M3'S, AMP, and A4'S exerted no or only minor inhibitory effects on CYP2C9, CYP2C19, and CYP3A4 enzymes. M3'S and MYR caused considerable inhibitory actions on OATP1B1 at low micromolar concentrations (IC50 = 1.7 and 6.4 μM, respectively), while even their nanomolar levels resulted in strong inhibitory effects on OATP2B1 (IC50 = 0.3 and 0.4 μM, respectively). In addition, M3'S proved to be a substrate of OATP1B1 and OATP2B1. These results suggest that MYR-containing dietary supplements may affect the OATP-mediated transport of certain drugs, and OATPs are involved in the tissue uptake of M3'S.
650    _2
$a lidé $7 D006801
650    12
$a flavonoidy $x farmakologie $7 D005419
650    12
$a přenašeče organických aniontů $x metabolismus $7 D027361
650    12
$a polypeptid C přenášející organické anionty $x metabolismus $7 D027381
650    _2
$a cytochrom P-450 CYP3A $x metabolismus $7 D051544
650    _2
$a flavonoly $x farmakologie $7 D044948
650    _2
$a sírany $x metabolismus $7 D013431
650    _2
$a sérový albumin $x metabolismus $7 D012709
650    _2
$a cytochrom P450 CYP2C9 $x metabolismus $7 D065729
650    _2
$a systém (enzymů) cytochromů P-450 $x metabolismus $7 D003577
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kaci, Hana $u Drug Resistance Research Group, Institute of Molecular Life Sciences, Research Centre for Natural Sciences, HUN-REN, Budapest, Hungary $u Doctoral School of Biology, Institute of Biology, Eötvös Loránd University, Budapest, Hungary
700    1_
$a Valentová, Kateřina $u Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic $1 https://orcid.org/0000000277145350 $7 xx0034397
700    1_
$a Bakos, Éva $u Drug Resistance Research Group, Institute of Molecular Life Sciences, Research Centre for Natural Sciences, HUN-REN, Budapest, Hungary
700    1_
$a Özvegy-Laczka, Csilla $u Drug Resistance Research Group, Institute of Molecular Life Sciences, Research Centre for Natural Sciences, HUN-REN, Budapest, Hungary $1 https://orcid.org/0000000297216339
700    1_
$a Poór, Miklós $u Department of Laboratory Medicine, Medical School, University of Pécs, Pécs, Hungary $u Molecular Medicine Research Group, János Szentágothai Research Centre, University of Pécs, Pécs, Hungary $1 https://orcid.org/0000000314257459
773    0_
$w MED00190080 $t Pharmacology research & perspectives $x 2052-1707 $g Roč. 12, č. 5 (2024), s. e70021
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39344282 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024111239 $b ABA008
999    __
$a ok $b bmc $g 2201536 $s 1230699
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 12 $c 5 $d e70021 $e - $i 2052-1707 $m Pharmacology research & perspectives $n Pharmacol Res Perspect $x MED00190080
GRA    __
$a ÚNKP-23-4 $p Nemzeti Kutatási, Fejlesztési és Innovaciós Alap
GRA    __
$a 23-04654S $p Grantová Agentura České Republiky
GRA    __
$a FK138184 $p Nemzeti Kutatási Fejlesztési és Innovációs Hivatal
GRA    __
$a K138518 $p Nemzeti Kutatási Fejlesztési és Innovációs Hivatal
GRA    __
$a BO/00381/21 $p Magyar Tudományos Akadémia
LZP    __
$a Pubmed-20241015

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...